Partner Adam Finerman and Associates Scott Kilian-Clark and Michael Greubel are supporting client Enzo Biochem, Inc., as it reviews strategic alternatives received regarding a potential transaction. The company’s board of directors has formed a special committee of independent directors to evaluate a range of opportunities in order to maximize value for shareholders. These include a potential strategic transaction, business combination, full sale of the company or return of excess capital to shareholders.
With comprehensive manufacturing capabilities in the U.S. and Europe providing an advantageous position in the life sciences market, Enzo Biochem has operated as a life sciences company for more than 45 years, focusing on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins. There is no timetable set for the review process and there will be no further announcements on the strategic review process unless and until such disclosure is appropriate or necessary.
Original source can be found here.